{"entity":{"type":"insider","cik":"0001714982","url":"/insider/0001714982","json_url":"/insider/0001714982.json","name":"Oltmans Curtis Gale","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":6,"n_filings":6,"first":"2019-01-17","last":"2025-12-17","span_basis":"filed_date"},"name_variants":[{"name":"Oltmans Curtis Gale","source":"filing","n_filings":6,"first_seen":"2019-01-17","last_seen":"2025-12-17"}],"transactions":[{"id":4532289,"accession":"0001193125-25-322740","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-25-322740","line_url":"/filing/0001193125-25-322740#line-1","is_derivative":false,"issuer_cik":"0001680581","issuer_name":"Fulcrum Therapeutics, Inc.","issuer_ticker":"FULC","issuer_name_source":null,"issuer_url":"/issuer/0001680581","owner_cik":"0001714982","owner_name":"Oltmans Curtis Gale","owner_display_name":"Oltmans Curtis Gale","owner_url":"/insider/0001714982","role":"Officer (Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3452.0,"shares_display":"3,452","price_per_share":12.92,"price_display":"12.92","price_state":"stated","total_value":44599.84,"total_display":"44,599.84","total_whole":"44,600","shares_owned_after":10252.0,"shares_owned_after_display":"10,252","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-12-15","filed_date":"2025-12-17","scope":"insider"},{"id":5031163,"accession":"0000899243-21-026556","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-026556","line_url":"/filing/0000899243-21-026556#line-1","is_derivative":false,"issuer_cik":"0001680581","issuer_name":"Fulcrum Therapeutics, Inc.","issuer_ticker":"FULC","issuer_name_source":null,"issuer_url":"/issuer/0001680581","owner_cik":"0001714982","owner_name":"Oltmans Curtis Gale","owner_display_name":"Oltmans Curtis Gale","owner_url":"/insider/0001714982","role":"Officer (SVP, General Counsel)","role_mark":"O","role_mark_label":"Officer (SVP, General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, General Counsel","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1088.0,"shares_display":"1,088","price_per_share":9.01,"price_display":"9.01","price_state":"stated","total_value":9802.88,"total_display":"9,802.88","total_whole":"9,803","shares_owned_after":1088.0,"shares_owned_after_display":"1,088","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-28","filed_date":"2021-06-29","scope":"insider"},{"id":8370622,"accession":"0001562180-19-000816","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001562180-19-000816","line_url":"/filing/0001562180-19-000816#line-3","is_derivative":false,"issuer_cik":"0001100412","issuer_name":"ARRAY BIOPHARMA INC","issuer_ticker":"ARRY","issuer_name_source":null,"issuer_url":"/issuer/0001100412","owner_cik":"0001714982","owner_name":"Oltmans Curtis Gale","owner_display_name":"Oltmans Curtis Gale","owner_url":"/insider/0001714982","role":"Officer (General Counsel)","role_mark":"O","role_mark_label":"Officer (General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":40000.0,"shares_display":"40,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":800000.0,"total_display":"800,000.00","total_whole":"800,000","shares_owned_after":15021.0,"shares_owned_after_display":"15,021","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-05","filed_date":"2019-02-07","scope":"insider"},{"id":8719369,"accession":"0001562180-19-000564","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-19-000564","line_url":"/filing/0001562180-19-000564#line-2","is_derivative":false,"issuer_cik":"0001100412","issuer_name":"ARRAY BIOPHARMA INC","issuer_ticker":"ARRY","issuer_name_source":null,"issuer_url":"/issuer/0001100412","owner_cik":"0001714982","owner_name":"Oltmans Curtis Gale","owner_display_name":"Oltmans Curtis Gale","owner_url":"/insider/0001714982","role":"Officer (General Counsel)","role_mark":"O","role_mark_label":"Officer (General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14029.0,"shares_display":"14,029","price_per_share":18.0001,"price_display":"18.00","price_state":"stated","total_value":252523.4029,"total_display":"252,523.40","total_whole":"252,523","shares_owned_after":3921.0,"shares_owned_after_display":"3,921","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-01-25","filed_date":"2019-01-29","scope":"insider"},{"id":8577322,"accession":"0001562180-19-000430","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-19-000430","line_url":"/filing/0001562180-19-000430#line-2","is_derivative":false,"issuer_cik":"0001100412","issuer_name":"ARRAY BIOPHARMA INC","issuer_ticker":"ARRY","issuer_name_source":null,"issuer_url":"/issuer/0001100412","owner_cik":"0001714982","owner_name":"Oltmans Curtis Gale","owner_display_name":"Oltmans Curtis Gale","owner_url":"/insider/0001714982","role":"Officer (General Counsel)","role_mark":"O","role_mark_label":"Officer (General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1251.0,"shares_display":"1,251","price_per_share":18.0,"price_display":"18.00","price_state":"stated","total_value":22518.0,"total_display":"22,518.00","total_whole":"22,518","shares_owned_after":3921.0,"shares_owned_after_display":"3,921","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-01-18","filed_date":"2019-01-23","scope":"insider"},{"id":7962625,"accession":"0001562180-19-000338","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-19-000338","line_url":"/filing/0001562180-19-000338#line-2","is_derivative":false,"issuer_cik":"0001100412","issuer_name":"ARRAY BIOPHARMA INC","issuer_ticker":"ARRY","issuer_name_source":null,"issuer_url":"/issuer/0001100412","owner_cik":"0001714982","owner_name":"Oltmans Curtis Gale","owner_display_name":"Oltmans Curtis Gale","owner_url":"/insider/0001714982","role":"Officer (General Counsel)","role_mark":"O","role_mark_label":"Officer (General Counsel)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"General Counsel","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":19720.0,"shares_display":"19,720","price_per_share":18.0598,"price_display":"18.06","price_state":"stated","total_value":356139.256,"total_display":"356,139.26","total_whole":"356,139","shares_owned_after":3921.0,"shares_owned_after_display":"3,921","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-01-15","filed_date":"2019-01-17","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":6,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":5,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":6},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001680581","name":"Fulcrum Therapeutics, Inc.","url":"/issuer/0001680581","role":"Officer (Chief Legal Officer)","n_filings":2,"first_seen":"2021-06-29","last_seen":"2025-12-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001100412","name":"ARRAY BIOPHARMA INC","url":"/issuer/0001100412","role":"Officer (General Counsel)","n_filings":4,"first_seen":"2019-01-17","last_seen":"2019-02-07"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001714982","retrieved_at":"2026-08-24T05:25:55+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}